R. Douglas Bruce, MD
Lead Harm Reduction Consultant
Dr. Doug Bruce’s interests reside at the intersection of substance abuse/dependence and infectious diseases, particularly HIV and Hepatitis C. He serves as lead harm reduction consultant at Pangaea Global AIDS Foundation where his work focuses on the development of comprehensive treatment programs for injection drug users to reduce the spread of HIV. Doug is an assistant professor at Yale University's School of Medicine and the Yale School of Public Health.
Doug has worked clinically in the treatment of HIV and Hepatitis C in drug treatment settings, jail/prison, and in mobile healthcare settings. He has assisted in the development and implementation of buprenorphine in each of these clinical environments. Finally, he has worked over the last several years training medical providers on evidenced based treatments for addiction and HIV.
Doug has trained clinical providers from Armenia, Azerbaijan, China, Georgia, Indonesia, Kazakhstan, Kyrgyzstan, Lithuania, Malaysia, Moldova, Poland, Tajikistan, The Russia Federation, and Ukraine.
Doug is currently the Medical Director of South Central Rehabilitation Center in New Haven, Connecticut, which is the first Federally Qualified Health Center (FQHC) to become an integrated health clinic: providing addiction medicine (buprenorphine and methadone), primary care (including HIV and Hepatitis C treatments), and mental health treatment all in one integrated setting.
His scholarly work focuses on the intersection of substance abuse/dependence and infectious diseases, particularly HIV and Hepatitis C. He is the recipient of a NIDA Career Development Award to improve health outcomes among drug users at the intersection of infectious diseases (especially HIV and HCV) and addiction. There are several specific sub-themes that are embedded in that overall focus and they are: 1) integration efforts to improve health outcomes; 2) pharmacokinetic interaction studies between HIV/HCV/TB treatments and treatments for substance dependence (e.g., buprenorphine/methadone); 3) ethical issues regarding the conduct of research and the provision of clinical care at the intersection of infectious diseases and addiction.
Doug received a B.S., Houston Baptist University, 1993, (cum laude); an M.D., University of Texas Southwestern Medical School at Dallas, 1997; an M.A., Yale University Divinity School, philosophical theology, 2003; and an M.Sc., Yale University School of Public Health, chronic disease epidemiology, 2008.
- Bruce RD. Methadone as HIV Prevention: High Volume Methadone Sites to Decrease HIV Incidence Rates in Resource Limited Settings. International Journal of Drug Policy. 2010; 21(2): 122-4
- Bruce RD, Kresina TF, McCance-Katz EF. Medication Assisted Treatment and HIV/AIDS: Aspects in Treating HIV-Infected Drug Users. AIDS. 2010; 24(3):331-40.
- Bruce RD, Schleifer RA. Ethical and Human Rights Imperatives to Ensure Harm Reduction Services in Prison. International Journal of Drug Policy, 2008; 19(1):17-23.
- Bruce RD, Altice FL. Clinical Care of the HIV-Infected Drug User. Infectious Disease Clinics of North America, 2007 Mar; 21:149-179.
- Bruce RD, Dvoryak S, Sylla LN, Altice FL. HIV Treatment Access and Scale-Up for Delivery for IDU in Ukraine with Opiate Substitution Therapy with Buprenorphine – Program Description and Policy Implications. International Journal of Drug Policy, 2007 Aug; 18(4): 326-328.